ASCO GU 2023

Bladder preservation strategies - promising data but no change in SoC yet?!

Robust DFS benefit, but lack of OS data leaves open questions

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

No change in SoC, but new genomic predictors for EV outcome

Atezo monotherapy for mUC

Final OS data show no significant benefit for chemo plus ICI

Urothelial cancer highlights from ASCO GU23

Final overall survival

Pembro for HR NMIBC

Update / German Real World Data M1 BC

PD-1 as combo in 1st line

IMvigor130: final OS

Benefit of neoadjuvant pembro for CE and CI patients

Re-shaping bladder cancer treatment

No final OS difference - but subgroups may benefit from Atezolizumab

Pembrolizumab in HR NIMBC

Checkpoint inhibition in adjuvant therapy

New data for pembro in HR NIMBC

NMIBC highlights from ASCO GU23

Exciting survival data for adjuvant NIVO

The bladder cancer highlights of ASCO GU

Urothelial cancer - hidden gems of the poster session

Impressive DFS with adjuvant Nivo in biomarker-positive patients

3 yrs outcome of Nivo for adjuvant therapy

PARPi are effective in PCa - which subgroups benefits most?

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

Refinando el tratamiento del cancere vejiga

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

The bladder cancer highlights of ASCO GU

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

Benefits and risks of precision medicine with PARPi

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

Benefit in all groups

Formula 509: Racing to a better straegy for radiotherapy

Controversy in ADT roundtable

Surgery vs. Radiation for N1 PCa: who wins?

mHSPC - new standard and more insights

Monotherapy is not any longer standard of care

Intensification of salvage therapy in high risk settings

ARASENS: triple independent of volume and risk

Normal baseline testosterone level is a strong predictor of post-ADT recovery

Doublet or all-in: the solution for all patients?

MMAI - a superior prognostic marker for high risk patients

New ways to target androgen receptor signaling

PARP and testing

ARASENS - post-hoc subgroup analysis

TALA ENZO with improved PFS in mCRPC

Rucaparib - ready for clinical practice in BRCAmut patients

Rucaparib - the new player?

PARPi combination in mCRPC

PARPi combo: all-comer treatment for mCRPC

PARPi study with different design

Encouraging results for Talazoparib

Propel - final OS

Tiebreaker for previous trials

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

PARPi & ARPi with wonderful data

PARPi are effective in PCa - which subgroup benefits most?

TALA in 1st line for all patients with mCRPC

Rucaparib: treatment option for biomarker-selected patients

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

Ny PARP hämmar studie med anna design

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

PARPi & ARPi με υπέροχα δεδομένα

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

Nya vägar att blockera androgenreceptor signalering

Updated data of CheckMate 9ER - impact on real-world therapy

Novel updates on cabozantinib in advance RCC

Theranostics in RCC - usefull tools for ccRCC?!

Hypothesis-generating differences in risks groups

Outcomes of patients with brain metastases treated with first-line therapies

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

Reassuring update of CM9ER with longer follow up

New therapy choices for renal cell cancer patients

Zircon-PET in RCC

First prospective data on 2nd line therapy after IO combination in mRCC

microbiom & CPI perspectives

High accuracy of miR371 to guide treatment selection after orchiectomy

Refining prediction of stage I seminoma

Mejorando la estimacion pronostica en Seminoma Estadio I